{"id":534537,"date":"2021-09-07T06:03:17","date_gmt":"2021-09-07T10:03:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/"},"modified":"2021-09-07T06:03:17","modified_gmt":"2021-09-07T10:03:17","slug":"greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/","title":{"rendered":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference"},"content":{"rendered":"

<\/p>\n

Greenwich LifeSciences to Participate in Citi\u2019s 16th<\/sup> Annual Biopharma Virtual Conference<\/b><\/p>\n

STAFFORD, Texas–(BUSINESS WIRE<\/a>)–
\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in Citi\u2019s 16th Annual BioPharma Virtual Conference from September 8-10, 2021. CEO Snehal Patel will participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.\n<\/p>\n

Citi\u2019s 16th Annual BioPharma Conference<\/b><\/p>\n

\nCiti\u2019s Biopharma conference is by invitation only and will feature fireside chats and presentations by select large pharma and biotech companies and key opinion leaders in a virtual format. Participating companies will also participate in one-on-one meetings.\n<\/p>\n

About Breast Cancer and HER2\/neu<\/i> Positivity<\/b><\/p>\n

\nOne in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2\/neu<\/i> (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.\n<\/p>\n

About Greenwich LifeSciences, Inc.<\/b><\/p>\n

\nGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2\/neu<\/i> protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2\/neu<\/i> 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338<\/i>). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial. For more information on Greenwich LifeSciences, please visit the Company\u2019s website at www.greenwichlifesciences.com<\/a><\/span> and follow the Company’s Twitter at https:\/\/twitter.com\/GreenwichLS<\/a>.\n<\/p>\n

About GP2 Immunotherapy Immune Response <\/b><\/p>\n

\nAs previously reported, GP2 immunotherapy generated GP2-specific immune responses, leading to no metastatic breast cancer recurrence in the HER2\/neu<\/i> 3+ population in the Phase IIb clinical trial, thus supporting GP2\u2019s mechanism of action. Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2\/neu<\/i> 3+ population immune response was similar to the HER2\/neu<\/i> 1-2+ population immune response, suggesting the potential to treat the HER2\/neu<\/i> 1-2+ population (including triple negative breast cancer) with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents. The broad based immune response suggests the potential for GP2 to treat other HER2\/neu<\/i> 1-3+ expressing cancers. For more information on GP2 immune response and clinical data, please visit the Company\u2019s clinical trial tab at https:\/\/greenwichlifesciences.com\/clinical-trials\/<\/a>.\n<\/p>\n

Forward-Looking Statement Disclaimer<\/b><\/p>\n

\nStatements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d “will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210907005306\/en\/<\/a><\/span><\/p>\n

Company Contact
\n<\/b>
Snehal Patel
\n
Investor Relations
\n
(832) 819-3232
\n
info@greenwichlifesciences.com<\/a><\/p>\n

Investor & Public Relations Contact for Greenwich LifeSciences
\n<\/b>
Dave Gentry
\n
RedChip Companies Inc.
\n
Office: 1-800-RED CHIP (733 2447)
\n
Cell: (407) 491-4498
\n
dave@redchip.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference STAFFORD, Texas–(BUSINESS WIRE)– Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in Citi\u2019s 16th Annual BioPharma Virtual Conference from September 8-10, 2021. CEO Snehal Patel will participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. Citi\u2019s 16th Annual BioPharma Conference Citi\u2019s Biopharma conference is by invitation only and will feature fireside chats and presentations by select large pharma and biotech companies and key opinion leaders in a virtual format. Participating companies will also … <\/p>\n

Continue reading “Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534537","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGreenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference STAFFORD, Texas–(BUSINESS WIRE)– Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in Citi\u2019s 16th Annual BioPharma Virtual Conference from September 8-10, 2021. CEO Snehal Patel will participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. Citi\u2019s 16th Annual BioPharma Conference Citi\u2019s Biopharma conference is by invitation only and will feature fireside chats and presentations by select large pharma and biotech companies and key opinion leaders in a virtual format. Participating companies will also … Continue reading "Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T10:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference\",\"datePublished\":\"2021-09-07T10:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/\"},\"wordCount\":808,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/\",\"name\":\"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-09-07T10:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk","og_description":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference STAFFORD, Texas–(BUSINESS WIRE)– Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced its participation in Citi\u2019s 16th Annual BioPharma Virtual Conference from September 8-10, 2021. CEO Snehal Patel will participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. Citi\u2019s 16th Annual BioPharma Conference Citi\u2019s Biopharma conference is by invitation only and will feature fireside chats and presentations by select large pharma and biotech companies and key opinion leaders in a virtual format. Participating companies will also … Continue reading \"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T10:03:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference","datePublished":"2021-09-07T10:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/"},"wordCount":808,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/","name":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-09-07T10:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210907005306r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/greenwich-lifesciences-to-participate-in-citis-16th-annual-biopharma-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Greenwich LifeSciences to Participate in Citi\u2019s 16th Annual Biopharma Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534537"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534537\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}